生成生物医药
GENB
12.09
-0.97
-7.43%
生成生物医药
US · GENB
#2875 按市值排名
上市于 2026
12.09
-0.97
-7.43%
实时 - 追踪5344个代码 - 心跳于532秒前
· 2026-10-16 19:45
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.4个百分点。
机构持股
- 机构持股比例
- 77.94% -0.41pp
- 机构数量
- 101 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund53.95%
Mutual Fund15.96%
Hedge Fund5.21%
Individual/Insider4.07%
Sovereign Wealth Fund1.63%
Endowment Fund0.87%
Public Company0.26%
Other17.98%
主要股东 截至 2026-06-30
Flagship Pioneering, Inc
48.83% · 62.67M 股
FMR
4.07% · 5.22M 股
Capital Research
3.28% · 4.22M 股
Braidwell LP
2.56% · 3.28M 股
Michael Nally
2.25% · 2.89M 股
T. Rowe Price Group, Inc.
1.68% · 2.16M 股
Norges Bank Investment Management
1.63% · 2.09M 股
Arch Venture Partners, L.P.
1.51% · 1.94M 股
HarbourVest Partners, LLC
1.34% · 1.72M 股
BlackRock
1.29% · 1.66M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪42份申报 · 19次买入 · 2次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Flagship Pioneering, Inc | -- | 48.83% |
| Michael Nally | Chief Executive Officer | 2.25% |
| Stéphane Bancel | Independent Director | 0.92% |
| Gevorg Grigoryan | Chief Technology Officer | 0.51% |
| Frances Arnold | Independent Director | 0.36% |
| Noubar Afeyan | Co-founder & Independent Chair of the Board | 0.02% |
| Jane Mendillo | Independent Director | 0.00% |
| Jason Silvers | President, CFO & Treasurer | 0.00% |
| Beth Grous | Chief Human Resources Officer | 0.00% |
| Paul Parker | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-01 | Frances Arnold | Independent Director | Intent to Sell (Form 144) | -32,210 | $16.16 |
| 2026-08-31 | Frances Arnold | Independent Director | Automatic Disposition | -1,000 | $16.00 |
| 2026-03-03 | Michael Nally | Chief Executive Officer | Open Market Acquisition | +20,000 | $12.00 |
| 2026-03-01 | Jane Mendillo | Independent Director | Private Acquisition | +1,500 | $16.00 |
| 2026-03-01 | Stéphane Bancel | Independent Director | Derivative Exercise and Retained | +724,160 | -- |
| 2026-03-01 | Michael Nally | Chief Executive Officer | Derivative Exercise and Retained | +658,327 | -- |
| 2026-03-01 | Beth Grous | Chief Human Resources Officer | Private Acquisition | +300 | $16.00 |
| 2026-03-01 | Jason Silvers | President, CFO & Treasurer | Private Acquisition | +2,000 | $16.00 |
| 2026-02-25 | Flagship Pioneering, Inc | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Noubar Afeyan | Co-founder & Independent Chair of the Board | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Paul Parker | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Paul Parker | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Marsha Fanucci | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Marsha Fanucci | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Nancy Simonian | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Nancy Simonian | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Frances Arnold | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Frances Arnold | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Jane Mendillo | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Jane Mendillo | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:45:43 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
生成生物医药 讨论区 0 条评论